Cite
HARVARD Citation
Wermke, M. et al. (2016). Mammalian‐target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D‐MDS). British journal of haematology. pp. 917-924. [Online].